Ascletis Approved to Market Dual All-oral HCV Treatment

Ascletis Pharma of Hangzhou has been approved to market its dual-drug, all-oral HCV treatment in China for hepatitis C. The approval adds Ravidasvir (Asclevir®) to Danoprevir (Ganovo®), the first direct-acting anti-viral agent (DAA) developed by a China company for HCV, which was approved in China two years ago. Together, the RDV/DNV regimen demonstrated a cure rate of 99 % after a 12-week treatment in genotype 1 patients. Since its inception, Ascletis has been working toward an all-oral, interferon-free treatment for HCV with near 100% efficacy. More details... Stock Symbol: (HK: 1672) Share this with colleagues: // //